Beta-arrestin-biased CB1 Receptor Agonists for Reduced Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid CB1 receptor ligands face challenges in distinguishing between Gi/o and beta-arrestin signaling pathways, leading to adverse side effects, and there is a need for therapeutically effective ligands with reduced adverse effects.
Innovation Solution
Development of compounds with a CB1 receptor-binding moiety that interacts non-covalently with specific amino acid residues, preventing binding to others, thereby favoring beta-arrestin mediated signaling over Gi/o pathway activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoid CB1 receptor ligands activate the Gi/o signaling pathway, then therapeutic effects are achieved, but adverse side effects occur
Solution Approach 1:
The invention segments the signaling pathway activation by designing ligands that selectively activate only the beta-arrestin pathway while avoiding Gi/o pathway activation. This is achieved through specific molecular structures (Formulas I-IV) that create steric hindrance to prevent Gi/o pathway engagement while maintaining beta-arrestin pathway activation, thereby separating therapeutic effects from adverse side effects
Solution Approach 2:
The ligands incorporate specific local structural features (directing moieties in Formulas I-IV) that create localized steric hindrance at the Gi/o pathway binding interface. This local modification allows the ligand to maintain overall binding affinity while selectively blocking Gi/o pathway activation, preserving therapeutic benefits without adverse effects
2Reliability
If conventional cannabinoid ligands bind to multiple amino acid residues, then receptor activation occurs, but pathway differentiation is lost
Solution Approach 1:
The invention extracts the beta-arrestin pathway activation function from the conventional multi-pathway activation mode. The ligand structures (Formulas I-IV) are designed to specifically engage beta-arrestin while excluding Gi/o pathway components, effectively isolating and activating only the desired signaling pathway for clear pathway differentiation
Solution Approach 2:
The directing moiety in the ligand structures acts as an intermediary that mediates selective pathway activation. It serves as a steric barrier that prevents Gi/o pathway engagement while allowing beta-arrestin pathway activation, thereby enabling clear differentiation between signaling pathways through controlled molecular interactions
Data Source
AI summary
The present invention provides compounds having a CB1 receptor-binding moiety and a directing moiety. In related aspects, the invention provides pharmaceutical compositions containing compounds of the invention, methods for inhibiting a pathway modulated in part by the CB1 receptor activity, and methods for treating a condition or disorder mediated in part by CB1 receptor activity. In certain embodiments, the compounds are compounds of Formula I. Methods of preparing compounds of Formula I are also described. In another aspect, the invention provides methods of identifying a selective agonist of the beta-arrestin pathway over the G-protein pathway.